Compare QH & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QH | ADIL |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 11.4M |
| IPO Year | 2019 | 2017 |
| Metric | QH | ADIL |
|---|---|---|
| Price | $3.35 | $3.49 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 10.3K | ★ 38.3K |
| Earning Date | 10-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.13 |
| 52 Week High | $12.81 | $9.75 |
| Indicator | QH | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 33.75 | 40.00 |
| Support Level | $3.00 | $2.38 |
| Resistance Level | $4.07 | $4.94 |
| Average True Range (ATR) | 0.27 | 0.42 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 30.57 | 31.33 |
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.